Suzhou Municipal Health Commission, Yice Tech, and JinYi Digital Join Forces to Establish a National Benchmark for AI-Powered Digital Pathology

On May 13, 2026, the Suzhou Municipal Health Commission, PathoAI (Hangzhou Yice Technology Co., Ltd.), and Suzhou Jinyi Digital Technology Co., Ltd. formally signed a strategic cooperation framework agreement,Joining Hands to Build a Nationally Leading City-Level Benchmark for Digital and Intelligent Pathology InnovationThis collaboration represents a significant practice by Suzhou in implementing the national “AI + Healthcare” strategy and taking the lead in promoting high-quality development of pathological diagnosis, offering a replicable and scalable “Suzhou Model” for the digital and intelligent transformation of pathology across China.

Currently, pathological diagnosis serves as the “gold standard” for disease diagnosis. However, the industry widely faces practical challenges such as workforce shortages, heavy slide-reading workloads, and variability in diagnostic subjectivity. Leveraging the advantages of AI technology—namely, 24/7 availability, high efficiency, and superior objectivity—this collaboration aims to deliver faster, more accurate, and more consistent services, thereby ensuring that high-quality pathological resources truly benefit a broader population.

As a national pioneer in the digital and intelligent transformation of healthcare, Suzhou is vigorously advancing the digitization of health services.“4+5+5+N”Overall Layout.AI pathology is one of the five key application areas, led and coordinated by the Suzhou Municipal Health Commission with unified deployment.。

As the lead entity for the project, the Suzhou Municipal Health Commission has fully leveraged its advantages in policy guidance, industry regulation, and resource coordination. By making effective use of the overall layout of the Suzhou Health and Medical AI Capability Center, it has coordinated the promotion of quality improvement and upgrading of regional pathology services and the construction of a digital health ecosystem, thereby providing robust policy guarantees and institutional support for pilot initiatives.

Secretary of the Party Leadership Group and Director of the Suzhou Municipal Health Commission

Leveraging the disciplinary leadership of the Department of Pathology at the First Affiliated Hospital of Soochow University, we jointly advance the construction of a regional pathology diagnosis center and a pathologist alliance, providing professional support for clinical application, quality control, and standardized development.

Director, Department of Pathology, The First Affiliated Hospital of Soochow University

As one of the first companies in China to obtain a Class III medical device registration certificate for pathology AI and a leading innovator firmly positioned in the first tier of large AI models for pathology, PathoAI leverages its independently developed InsightPath multimodal large model as its core technological foundation. The company has built an integrated software-and-hardware product matrix covering four major scenarios: cytopathology, histopathology, immunohistochemistry, and molecular pathology. It provides comprehensive digital and intelligent pathology services spanning intelligent scanning, cloud storage, computer-aided diagnosis, quality control, as well as teaching, training, and research analysis, thereby fully empowering the construction of Suzhou’s city-level pathology data standards and algorithmic infrastructure.

Founder & CEO of PathoAI

As a locally based state-owned medical digitalization operations platform in Suzhou, Suzhou Jinyi Digital Technology Co., Ltd. leverages its advantages in local resource integration, task implementation, and ecosystem collaboration to ensure the efficient deployment, standardized operation, and sustainable management of pilot projects.

Deputy Secretary of the Party Committee and General Manager of Jiangsu Jinfu Digital Group & Chairman of Suzhou Jinyi Digital Technology Co., Ltd.

The three parties will deepen their collaboration across four key areas: first, enhancing the homogenization of pathological diagnosis, promoting the standardized application of AI in pathology, and delivering efficient, precise, and objective diagnostic services; second, jointly establishing pathological data standards and algorithmic infrastructure, advancing centralized storage of digital slides and cloud-based unification of diagnostic reports, while strengthening quality control throughout the entire workflow; third, providing in-depth support to Suzhou’s biopharmaceutical and CRO industries, facilitating new drug development, target discovery, and innovations in precision medicine, thereby fostering a synergistic ecosystem between clinical practice and industry; and fourth, creating provincial- and national-level demonstration scenarios to establish a replicable and scalable “Suzhou Model” for digital and intelligent pathology.

This strategic partnership represents a significant implementation of Suzhou’s “4+5+5+N” digital health strategy and serves as a model for the deep integration of policy, technology, and market forces. Upon implementation, the project will substantially enhance regional pathology service capabilities and quality control standards, support Suzhou in cultivating new quality productive forces in medical AI, and establish a national innovation hub for digital and intelligent pathology.

Looking ahead, the three parties will use the Suzhou pilot as a starting point to deepen collaboration, summarize experience, and optimize models, thereby promoting the transition of pathology AI from regional demonstration to nationwide adoption. By leveraging digital intelligence to reshape the value of pathological diagnosis, they aim to make greater contributions to the Healthy China initiative and the high-quality development of healthcare services in Suzhou.